Eli Lilly’s COVID-19 antibody picks up $871M in Q4—and carries blockbuster hopes for 2021

Eli Lilly’s COVID-19 antibody picks up $871M in Q4—and carries blockbuster hopes for 2021
esagonowsky
Fri, 01/29/2021 – 10:51